手术治疗HPV阳性口咽癌患者的切缘状态与复发
本研究纳入2012年5月至2021年12月接受原发经口机器人手术(TORS)的中危HPV阳性口咽鳞状细胞癌(OPSCC)患者,评估手术切缘对无进展生存期(PFS)的影响。69例患者中位随访47个月,全组总生存率(OS)为100%,PFS为88.9%;未接受辅助放疗者中,切缘紧密组与切缘清晰组的OS和PFS均为100%。结论认为切缘清晰相比切缘紧密并未带来显著的OS或PFS生存优势,即使省略辅助治疗亦然。
要点
- 中危HPV阳性OPSCC接受原发TORS后,切缘清晰与切缘紧密的OS和PFS均无显著差异。
- 未接受辅助放疗者中,切缘紧密组和切缘清晰组的OS和PFS均为100%。
- 全组中位随访47个月,OS为100%,PFS为88.9%。
核心结论
- 在因HPV阳性OPSCC接受TORS的患者中,切缘清晰相比切缘紧密未带来显著的OS或PFS生存优势,即使省略辅助治疗亦然。
研究设计与样本
- 回顾性评估2012年5月至2021年12月接受原发TORS的中危(T1-T2,切缘清晰≥3 mm或切缘紧密<3 mm,N1-N2)HPV阳性OPSCC患者,共69例纳入分析。
主要发现
- 全组中位随访47个月,OS为100%,PFS为88.9%。
- 未接受辅助放疗者中,切缘紧密组OS为100%、PFS为100%(中位随访47个月)。
- 切缘清晰组OS概率为100%、PFS概率为100%(中位随访47个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal margins for surgically treated human papilloma virus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) remain undefined. We evaluated the impact of surgical margins on progression-free survival (PFS) in patients with HPV+ OPSCC treated with primary transoral robotic surgery (TORS). METHODS: Patients undergoing primary TORS from May 2012 to December 2021 for intermediate-risk (T1-T2, resected to clear (≥ 3 mm) or close margins (< 3 mm), and N1-N2) HPV+ OPSCC were included. Survival outcomes were reviewed, and overall and PFS at 3 years posttreatment were determined using Kaplan-Meier analysis. RESULTS: A total of 69 subjects met inclusion criteria. At a median follow-up of 47 months, overall survival (OS) was 100%, and the PFS was 88.9% for the entire subject group. Among subjects not receiving adjunctive radiotherapy (RT), those with close margins had an OS of 100% and a PFS of 100% (median follow-up 47 months). Subjects with clear margins had an OS probability of 100% and a PFS probability of 100% (median follow-up 47 months). CONCLUSION: In subjects undergoing TORS for HPV+ OPSCC, clear margins did not confer a significant OS or PFS survival advantage compared to those with close margins, even when adjuvant therapy was omitted.
引用
- Ausburn M, Pyne JM, Day AT, et al. Margin Status and Recurrence in Surgically Treated Patients With HPV+ Oropharyngeal Cancer. Laryngoscope. 2025. PMID: 40035290. doi:10.1002/lary.32091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。